MacroGenics, Inc. (MGNX)

Market Cap	462.80M
Revenue (ttm)	151.94M
Net Income (ttm)	-119.76M
Shares Out	65.00M
EPS (ttm)	-1.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	802,236
Open	6.87
Previous Close	6.69
Day's Range	6.80 - 7.36
52-Week Range	2.13 - 10.20
Beta	1.95
Analysts	Buy
Price Target	10.61 (+49.02%)
Earnings Date	May 2, 2023

About MGNX

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugat...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 10, 2013
• Employees: 427
• Stock Exchange: NASDAQ
• Ticker Symbol: MGNX

Financial Performance

In 2022, MacroGenics's revenue was $151.94 million, an increase of 96.19% compared to the previous year's $77.45 million. Losses were -$119.76 million, -40.75% less than in 2021.

Analyst Forecast

According to 18 analysts, the average rating for MGNX stock is "Buy." The 12-month stock price forecast is $10.61, which is an increase of 49.02% from the latest price.

Price Target

$10.61

(49.02% upside)

Analyst Consensus: Buy